Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting
Preliminary data from ongoing Phase 1/2 trial show dose dependent target engagement and provide clinical proof-of-mechanism for GRWD5769, demonstrating ability to modulate the human immunopeptidome with therapeutic intent for first...
Read More
Grey Wolf Therapeutics to Present First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting
Interim Results from Ongoing Phase 1/2 Clinical Trial of Lead Immuno-Oncology Candidate to be Reported in Poster Presentation OXFORD, UK – May 29, 2024 – Grey Wolf Therapeutics, a...
Read More
Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology
Brings Total Series B Funds Raised to Nearly $100 Million Proceeds to Support Broadening Scope of Ongoing Clinical Trial of GRWD5769; First Clinical Data to be Reported at ASCO 2024...
Read More
Promising preclinical data reported at AACR 2023
GWT reports promising preclinical data from research collaboration with Immunocore in oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023...
Read More
Announcing the dosing of first patient in our clinical study
GWT announces dosing of first patient in phase 1/2 clinical study of GRWD5769 in patients with advanced solid tumours...
Read More
$49 Million Series B Financing Oversubscribed
Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced the closing of an oversubscribed $49 million Series B...
Read More